Role of S100A3 in human colorectal cancer and the anticancer effect of cantharidinate

Experimental and Therapeutic Medicine

Volumn 6, Issue 6, 2013, Pages 1499-1503

  Liu, Bin ^a   Sun, Wen Yi ^b   Zhi, Chen Yang ^c   Lu, Tian Cheng ^d   Gao, Hai Mei ^a   Zhou, Jian Hua ^c   Yan, Wei Qun ^b   Gao, Hai Cheng ^b  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

^c CHANGCHUN UNIVERSITY   (China)

^d JILIN AGRICULTURAL UNIVERSITY   (China)

Author keywords

Cantharidinate; Colorectal cancer; S100A3

Indexed keywords

ANTINEOPLASTIC AGENT; CANTHARIDINATE; EOSIN; FLUOROURACIL; HEMATOXYLIN; PROTEIN S 100 A3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL CULTURE; CHINESE MEDICINE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; STAINING;

EID: 84888400432     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1344     Document Type: Article

References (26)

1. Deng X, Cao Y, Liu Y, Li F, et al: Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer. Mol Carcinog 52: 255-264, 2013.
2. Potter JD: Colorectal cancer: molecules and populations. J Natl Cancer Inst 91: 916-932, 1999.
3. Domínguez-Ayala M, Díez-Vallejo J and Comas-Fuentes A: Missed opportunities in early diagnosis of symptomatic colorectal cancer. Rev Esp Enferm Dig 104: 343-349, 2012.
4. Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol 6: 479-507, 2011.
5. Chan EC, Barry MJ, Vernon SW and Ahn C: Brief report: physicians and their personal prostate cancer-screening practices with prostate-specific antigen. A national survey. J Gen Intern Med 21: 257-259, 2006.
6. Simoglou C, Gymnopoulou E, Simoglou L, Gymnopoulou M, Nikolaou K and Gymnopoulos D: Surgery for colorectal cancer in the small town of Komotini. J Multidiscip Healthc 5: 273-276, 2012.
7. Kotzev I, Mirchev M, Manevska B, Ivanova I and Kaneva M: Risk and protective factors for development of colorectal polyps and cancer (Bulgarian experience). Hepatogastroenterology 55: 381-387, 2008.
8. Posner MR: Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. Oncologist 10 (Suppl 3): S11-S19, 2005.
9. Fritz G, Mittl PR, Vasak M, Grutter MG and Heizmann CW: The crystal structure of metal-free human EF-hand protein S100A3 at 1.7-A resolution. J Biol Chem 277: 33092-33098, 2002.
10. Kizawa K, Takahara H, Unno M and Heizmann CW: S100 and S100 fused-type protein families in epidermal maturation with special focus on S100A3 in mammalian hair cuticles. Biochimie 93: 2038-2047, 2011.
11. Kizawa K, Inoue T, Yamaguchi M, Kleinert P, Troxler H, Heizmann CW and Iwamoto Y: Dissimilar effect of perming and bleaching treatments on cuticles: advanced hair damage model based on elution and oxidation of S100A3 protein. J Cosmet Sci 56: 219-226, 2005.
12. Kizawa K, Unno M, Takahara H and Heizmann CW: Purification and characterization of the human cysteine-rich S100A3 protein and its pseudo citrullinated forms expressed in insect cells. Methods Mol Biol 963: 73-86, 2013.
13. 2+ binding states. Biochim Biophys Acta 1833: 1712-1719, 2013.
14. van Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D, Bower GD, Briggs GM, Rossleigh MA, Taylor DJ and George J: Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 27: 4089-4095, 2009.
15. Gerber DE: Targeted therapies: a new generation of cancer treatments. Am Fam Physician 77: 311-319, 2008.
16. Dehmer GJ, Douglas JS Jr, Abizaid A, Berg JW, Day J, Hall R, Leon MB, Hijazi ZM, Marchlinski F, Park SJ and Popma JJ: SCAI/ACCF/HRS/ESC/SOLACI/APSIC statement on the use of live case demonstrations at cardiology meetings: assessments of the past and standards for the future. Heart Rhythm 7: 1522-1535, 2010.
17. Liu HG and Huang HX: Overview pharmacokinetic about traditional Chinese medicine in recent 10 years. Zhongguo Zhong Yao Za Zhi 32: 2346-2348, 2007 (In Chinese).
18. Honkanen RE: Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Letters 330: 283-286, 1993.
19. Deng LP, Dong J, Cai H and Wang W: Cantharidin as an antitumor agent: a retrospective review. Curr Med Chem 20: 159-166, 2013.
20. Huang YP, Ni CH, Lu CC, Chiang JH, Yang JS, Ko YC, Lin JP, Kuo JH, Chang SJ and Chung JG. Suppressions of migration and invasion by cantharidin in TSGH-8301 human bladder carcinoma cells through the inhibitions of matrix metalloproteinase-2/-9 signaling. Evid Based Complement Alternat Med 2013: 190281, 2013.
21. Zhan YP, Huang XE, Cao J, Lu YY, Wu XY, Liu J, Xu X, Xu L, Xiang J and Ye LH: Clinical study on safety and efficacy of Qinin® (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev 13: 4773-4776, 2012.
22. Kim YM, Ku MJ, Son YJ, Yun JM, Kim SH and Lee SY: Anti-metastatic effect of cantharidin in A549 human lung cancer cells. Arch Pharm Res 36: 479-484, 2013.
23. Yeh CH, Yang YY, Huang YF, Chow KC and Chen MF: Induction of apoptosis in human Hep3B hepatoma cells by norcantharidin through a p53 independent pathway via TRAIL/DR5 signal transduction. Chin J Integr Med 18: 676-682, 2012.
24. Haggar FA and Boushey RP: Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22: 191-197, 2009.
25. BenZion I and Helveston EM: Use of telemedicine to assist ophthalmologists in developing countries for the diagnosis and management of four categories of ophthalmic pathology. Clin Ophthalmol 1: 489-495, 2007.
26. Gerber DE: Targeted therapies: a new generation of cancer treatments. Am Fam Physician 77: 311-319, 2008.